JPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $46.00

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target decreased by JPMorgan Chase & Co. from $52.00 to $46.00 in a report published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

OLMA has been the subject of a number of other research reports. Citigroup dropped their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. HC Wainwright lowered their target price on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday. Guggenheim cut their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings cut shares of Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $42.40.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $10.63 on Thursday. The stock has a market capitalization of $930.13 million, a PE ratio of -5.01 and a beta of 2.03. Olema Pharmaceuticals has a 12-month low of $5.29 and a 12-month high of $36.26. The stock’s 50 day simple moving average is $11.24 and its 200 day simple moving average is $15.41. The company has a current ratio of 8.86, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.06). As a group, research analysts forecast that Olema Pharmaceuticals will post -2.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director directly owned 715,270 shares in the company, valued at approximately $8,282,826.60. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.56% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Bain Capital Life Sciences Investors LLC lifted its holdings in Olema Pharmaceuticals by 24.3% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after buying an additional 1,664,687 shares during the period. Paradigm Biocapital Advisors LP increased its holdings in shares of Olema Pharmaceuticals by 11.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after acquiring an additional 750,000 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Olema Pharmaceuticals by 5.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock valued at $106,013,000 after acquiring an additional 398,294 shares during the period. Jupiter Topco LLC bought a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth $88,803,000. Finally, BlackRock Inc. bought a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth $84,001,000. Institutional investors own 91.78% of the company’s stock.

Key Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Olema appointed Jason O’Byrne as chief financial officer. The leadership addition could support financial planning, capital management and the company’s continued development efforts. Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, while Goldman Sachs also initiated or reiterated a Buy view on OLMA. Continued bullish coverage may provide support for the stock and signals that analysts see substantial long-term value in Olema’s pipeline. Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals Olema Pharmaceuticals Receives a Buy from Goldman Sachs
• Neutral Sentiment: JPMorgan lowered its price target to $46 from $52 but retained an Overweight rating. The target reduction is a negative revision, although it still implies considerable upside from recent trading levels. JPMorgan Revises Olema Pharmaceuticals Price Target
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of losses of $2.44 per share in fiscal 2026 and $2.78 in 2027. The revisions point to expectations for larger or more persistent losses, despite the firm maintaining a Buy rating and $36 price target.
• Negative Sentiment: Olema’s latest quarterly results missed expectations, with a loss of $0.61 per share versus the consensus loss estimate of $0.55. Reports characterized the shares as gapping lower following the weak earnings, adding pressure to a stock already trading well below its 52-week high. Olema Pharmaceuticals Shares Gap Down Following Weak Earnings

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.